Drug Profile
Research programme: P2X7 receptor antagonists - Asahi Kasei Pharma/RaQualia Pharma
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Asahi Kasei Pharma Corp; RaQualia Pharma
- Class Analgesics
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain